| abstract |
In the present invention, at least one low water-soluble active agent, preferably an endothelin converting enzyme (ECE) inhibitor and / or a neutral endopeptidase (NEP) inhibitor, in an amount exceeding 10% w / w of the composition. An improved oral pharmaceutical composition comprising an alkaline system comprising a mixture of at least two alkaline compounds, more preferably in a ratio of 1:20 to 20: 1, wherein the active agent is SLV-306 or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer or derivative thereof; preferably two alkaline systems in an amount exceeding 10% w / w of the composition Compositions comprising a mixture of alkaline compounds and optionally comprising one or more pharmaceutically acceptable additives are provided. Also provided are methods of making such improved compositions and methods of using such compositions. |